Enteral Nutrition Market Share, Size, Trends and Revenue Forecast 2030

[Research Report] The enteral nutrition market size is projected to surge from US$ 8,276.93 million in 2022 to US$ 13,204.19 million by 2030; the market is estimated to grow at a CAGR of 6.0% during 2022–2030.

Analyst Perspective:

The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease, and new product launches drive the enteral nutrition market. An upsurge in the awareness regarding cancer as well as the requirement of proper nutritional intake during and after the disease treatment benefits the enteral nutrition market. Governments are also taking initiatives to bolster the adoption of enteral nutrition among people undergoing cancer treatment. For instance, the Canadian Cancer Society is creating awareness about enteral nutrition and tube feeding among cancer patients. Further, the BC Home Enteral Nutrition (HEN) Program—in collaboration with Oley Foundation—supports patients in British Columbia and the Yukon with specialized nutrition needs by creating awareness through advocacy, education, and networking to help patients live enhanced lives. Key players in the enteral nutrition market are focusing on the R&D of new products and the launch of these products. In November 2020, Abbott launched Similac Pro-Advance with 2'-Fucosyllactose Oligosaccharide. It is the first enteral nutrition product launched in Canada that can be used as a novel ingredient in infant formulae.

Market Overview:

Enteral nutrition is given to a patient when they do not receive enough nutrition that is required for a healthy lifestyle through their daily food consumption. Enteral nutrition refers to any method of feeding that uses the gastrointestinal (GI) tract to deliver nutrition and calories to fulfill an individual’s caloric requirements. It can include a normal oral diet, liquid supplements, or delivery using a tube (tube feeding). It is provided to patients whose energy and nutritional needs cannot be met by a regular food intake.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Enteral Nutrition Market: Strategic Insights

Enteral Nutrition Market

• 
  CAGR (2022 - 2030)

  6.0%
• Market Size 2022
  US$ 8.28 Billion
• Market Size 2030
  US$ 13.2 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Nestl
• Danone S A
• Abbott Laboratories
• FrieslandCampina
• Fresenius SE and Co KGaA
• B Braun SE
• Dr Sch r AG
• Arla Food
• Reckitt Benckiser

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product Type

• General and Disease Specific

Application

• Gastrointestinal Disorders
• Metabolic/Inborn Errors of Metabolism
• Food Allergy
• Renal Disease
• Liver Disease
• Oncology
• Neurology

Age Group

• Adult and Pediatric

Distribution Channel

• Hospital Pharmacies
• Retail Stores
• E-Commerce

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Driver:

Increasing Cases of Malnutrition and Premature Births Drive Global Enteral Nutrition Market

Malnutrition includes being undernourished, overweight, or obese, having inadequate vitamins or minerals, and having a noncommunicable disease due to a bad diet. As per the World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021 globally. Additionally, 39 million children under the age of 5 were overweight, 149 million had stunted growth and development due to a chronic lack of nutrient-rich food in their diets, and 45 million were weakened (too thin for height). Nutritional support delivered through enteral and parenteral means, depending on the need, is an important and appropriate way of treating most malnutrition cases. Thus, the huge burden of malnutrition in children and adults drives the demand for enteral nutrition formulae and products.

Preterm birth refers to a baby being born too early, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm births (more than 1 in 10) were reported worldwide in 2020. Additionally, most preterm births (more than 60%) occurred in Southern Asia and Sub-Saharan Africa in 2021, which is becoming a global concern. On average, 12% of babies in low-income countries are born too early, compared to 9% in high-income countries. A large number of premature babies suffer from low weight and undeveloped immunity, which puts their life at risk. Most medical guidelines advise enteral nutrition for supporting the optimal growth of preterm infants if they are unable to drink, suck, swallow, and breathe. Also, parenteral nutrition is preferred in such babies due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. Hence, the increasing number of preterm births is driving the global enteral nutrition market growth .

Segmental Analysis:

Based on product type, the enteral nutrition market is bifurcated into general and disease specific. The general segment held a larger market share in 2022. The disease-specific product type is anticipated to register a higher CAGR of 6.1% during 2022–2030. General or standard formulas or whole protein formulas are designed for adults or children with normal digestion. Standard formulas include all nutrients required to maintain health. A few standard formulas can be used for both enteral feeding and parenteral feeding. Standard formulas provide 10–25% energy from protein sources, including milk, whey, casein, caseinates, or soy protein. Protein in formulas provides 4 kcal/gm. Standard feeding formulas are typically well tolerated and contain complete protein and long-chain fat. Calorically dense formulas (1.5–2.0 kcal/ml) are usually required to provide adequate energy. These are intended and recommended for patients who require nutrition to maintain health and who suffer from digestion problems. Nestlé and Abbott are among the companies that offer standard protein enteral feeding formulations. Jevity 1.0 Cal, manufactured by Abbott, is composed of milk and soy protein. It is a standard protein product with fiber content and is suitable for lactose-intolerant people.

Regional Analysis:

North America is the dominating region in the enteral nutrition market. The North America enteral nutrition market was valued at US$ 3,206.58 million in 2022 and is projected to reach US$ 5,187.48 million by 2030; it is expected to register a CAGR of 6.2% during 2022–2030. The North America enteral nutrition market is segmented into the US, Canada, and Mexico. The rising prevalence of chronic diseases, growing strategic developments by market players, and increasing preference for enteral and parenteral nutrition contribute to the enteral nutrition market progress in this region. Moreover, growing knowledge among individuals about the benefits of medical nutrition, such as tube feeding, in treating chronic health conditions further contributes to the enteral nutrition market growth. The US government is working on making people aware of enteral nutrition through initiatives. For instance, the Feeding Tube Awareness Foundation creates awareness about adopting feeding tubes as a lifesaving medical intervention and helps parents of tube-fed children. The foundation celebrated the annual Feeding Tube Awareness Week from February 4 to February 8, 2019. Further, Nutricia and many similar companies are committed to raising awareness among the population. In January 2023, Nestlé Health Science invested ~US$ 43 million in the expansion of its manufacturing facility in Eau Claire, Wisconsin, US. To expand this facility, the company would add two new production lines to ramp up the manufacturing of an array of medical nutrition products, such as tube-feeding formulas and nutritional drinks. In February 2021, Amsino Medical Group received the FDA 510(k) clearance for its Puggle enteral feeding pump and feeding set for pediatric and adult patients.

Europe holds the second largest share of the enteral nutrition market. Market growth in this region is mainly attributed to the increasing geriatric population, rising incidence of chronic diseases and neurological disorders such as stroke and cerebral aneurysms, and product innovations by the players operating in the region. According to the Association of the Scientific Medical Societies in Germany, patients with severe gastrointestinal defects, such as radiation enteritis, can benefit from parenteral nutrition. In most cases, artificial nutrition stabilizes or increases body weight and body fat mass. The presence of local market players in the country is favoring the market growth. For instance, the Servona Group is among the top manufacturers of medical products, medical aids, and complete home care providers in Germany. It offers enteral nutrition products and feeding pumps. According to the company, ~120,000 patients in Germany rely on enteral nutrition.

The Asia Pacific enteral nutrition market holds the fastest CAGR. The factors contributing to the market progress in this region include the rising prevalence of chronic diseases and the growing presence of market players across the region, conferring the highest manufacturing of enteral nutrition products. Furthermore, supportive government initiatives and research in the field of nutrition boost market growth. Countries such as Australia, India, and South Korea are estimated to witness various growth opportunities due to the rising development in the healthcare sector. In addition, governments of these countries are increasing their efforts to provide enteral and parenteral nutrition. In Asia Pacific region China holds the largest share of of the enteral nutrition market. The rising prevalence of neurological diseases and the growing adoption of enteral nutrition are boosting the market's growth. China has experienced a significant rise in the elderly population. Stroke is the leading cause of death among older people across the country. According to the study published in Elsevier, in 2020, 17.8 million cases of stroke, 3.4 million new strokes, and 2.3 million stroke-related deaths were reported. The growing number of cancer cases in China is driving the enteral nutrition market. Enteral nutrition in cancer patients increases nutrient intake as normal food consumption is insufficient. As per the data released by the World Health Organization in April 2020, in China, there were ~4,568,754 new cancer cases and 3,002,899 deaths due to cancer. Every minute, approximately seven people are diagnosed with cancer, and four people die due to cancer in China.

Key Player Analysis:

The enteral nutrition market analysis consists of the players such as Nestlé, Danone S.A., Abbott Laboratories, FrieslandCampina, Fresenius SE and Co. KGaA, B. Braun SE, Dr. Schär AG, Arla Food, Reckitt Benckiser, Perrigo Company PLC, Fonterra Co-operative Group Limited, Kate Farms, and Nutritional Medicinals, LLC. Abbott Laboratories and Fresenius Kabi AG are the top two market players owing to their diversified product portfolio.

Enteral Nutrition Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the enteral nutrition market. A few recent key market developments are listed below:

• In January 2023, Nutricia launched Fortimel PlantBased Energy, its first plant-based, ready-to-drink oral nutritional supplement. The product is specifically formulated to fulfill the nutritional needs of malnourished populations or people at risk of malnutrition due to certain illness. Following the launch of Fortimel, the company plans to build on Danone's (parent company) expertise in plant nutrition to expand its Fortimel portfolio. The new product is available in the Netherlands, Denmark, Norway, Spain, Finland, and the Czech Republic.
• In June 2022, Nestlé Health Science acquired The Better Health Company (TBHC), the parent company of GO Healthy and Egmont, from CDH Investments and TBHC founding shareholders. Through this transaction, Nestlé Health Science would acquire TBHC in its entirety. This includes GO Healthy, a leading supplement brand of New Zealand; New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins, minerals, and supplements; and the Manuka honey brand, Egmont.
• In May 2022, Nestlé Health Science acquired Puravida, a premium Brazilian nutrition and health lifestyle brand. With this acquisition, NHSc intends to expand its consumer health portfolio in Brazil. Puravida's mix of products complements Nestlé Health Science’s portfolio, which offers oral nutritional supplements, protein powders, and ready-to-drink nutritional beverages in Brazil.
• In November 2021, Abbott Launched Similac 360 Total Care to support the immune system, digestive health, and brain development in babies. Similac 360 Total Care is the first and only infant formula in the US with a blend of five different HMOs, which are only found together in breast milk.